NO327220B1 - Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser - Google Patents

Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser Download PDF

Info

Publication number: NO327220B1
Authority: NO; Norway
Prior art keywords: pyrimidin; ethoxy; amide; bromo; yloxy
Prior art date: 2002-01-02

Application number

NO20043215A

Other languages

English (en)

Norwegian (no)

Other versions

NO20043215L (no

Inventor

Martin Bolli

Thomas Weller

Walter Fischli

Martine Clozel

Christophe Boss

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-02

Filing date

2004-07-29

Publication date

2009-05-18

2004-07-29 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2004-07-29 Publication of NO20043215L publication Critical patent/NO20043215L/no

2009-05-18 Publication of NO327220B1 publication Critical patent/NO327220B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 84
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 21
239000003814 drug Substances 0.000 title claims description 17
238000002360 preparation method Methods 0.000 title claims description 15
208000035475 disorder Diseases 0.000 title claims description 13
238000004519 manufacturing process Methods 0.000 title claims description 9
238000000034 method Methods 0.000 title claims description 8
229940079593 drug Drugs 0.000 title description 5
239000000203 mixture Substances 0.000 claims description 40
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 30
108050009340 Endothelin Proteins 0.000 claims description 27
102000002045 Endothelin Human genes 0.000 claims description 27
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 22
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
125000000714 pyrimidinyl group Chemical group 0.000 claims description 13
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
229910052760 oxygen Inorganic materials 0.000 claims description 10
239000001301 oxygen Substances 0.000 claims description 10
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 9
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 9
125000004076 pyridyl group Chemical group 0.000 claims description 9
125000003373 pyrazinyl group Chemical group 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 7
150000002367 halogens Chemical group 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 7
206010019280 Heart failures Diseases 0.000 claims description 6
206010020772 Hypertension Diseases 0.000 claims description 6
206010061218 Inflammation Diseases 0.000 claims description 6
208000001647 Renal Insufficiency Diseases 0.000 claims description 6
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims description 6
230000004054 inflammatory process Effects 0.000 claims description 6
201000006370 kidney failure Diseases 0.000 claims description 6
208000002815 pulmonary hypertension Diseases 0.000 claims description 6
201000001320 Atherosclerosis Diseases 0.000 claims description 5
208000019695 Migraine disease Diseases 0.000 claims description 5
206010040047 Sepsis Diseases 0.000 claims description 5
208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 5
208000006673 asthma Diseases 0.000 claims description 5
125000000753 cycloalkyl group Chemical group 0.000 claims description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
206010027599 migraine Diseases 0.000 claims description 5
125000002757 morpholinyl group Chemical group 0.000 claims description 5
210000000056 organ Anatomy 0.000 claims description 5
125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 4
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
201000004569 Blindness Diseases 0.000 claims description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
206010006458 Bronchitis chronic Diseases 0.000 claims description 4
206010008120 Cerebral ischaemia Diseases 0.000 claims description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
108010036949 Cyclosporine Proteins 0.000 claims description 4
206010011878 Deafness Diseases 0.000 claims description 4
206010012289 Dementia Diseases 0.000 claims description 4
208000010228 Erectile Dysfunction Diseases 0.000 claims description 4
208000010412 Glaucoma Diseases 0.000 claims description 4
206010018364 Glomerulonephritis Diseases 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 4
208000003782 Raynaud disease Diseases 0.000 claims description 4
208000012322 Raynaud phenomenon Diseases 0.000 claims description 4
206010038419 Renal colic Diseases 0.000 claims description 4
206010063897 Renal ischaemia Diseases 0.000 claims description 4
208000007107 Stomach Ulcer Diseases 0.000 claims description 4
206010001902 amaurosis Diseases 0.000 claims description 4
238000002399 angioplasty Methods 0.000 claims description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
229910052794 bromium Inorganic materials 0.000 claims description 4
206010006451 bronchitis Diseases 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
239000000460 chlorine Chemical group 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
208000007451 chronic bronchitis Diseases 0.000 claims description 4
229960001265 ciclosporin Drugs 0.000 claims description 4
208000029078 coronary artery disease Diseases 0.000 claims description 4
229930182912 cyclosporin Natural products 0.000 claims description 4
208000000718 duodenal ulcer Diseases 0.000 claims description 4
230000010370 hearing loss Effects 0.000 claims description 4
231100000888 hearing loss Toxicity 0.000 claims description 4
208000016354 hearing loss disease Diseases 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
201000001881 impotence Diseases 0.000 claims description 4
208000031225 myocardial ischemia Diseases 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
208000007232 portal hypertension Diseases 0.000 claims description 4
201000004240 prostatic hypertrophy Diseases 0.000 claims description 4
208000037803 restenosis Diseases 0.000 claims description 4
230000035939 shock Effects 0.000 claims description 4
208000007056 sickle cell anemia Diseases 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
238000002054 transplantation Methods 0.000 claims description 4
230000002792 vascular Effects 0.000 claims description 4
208000002249 Diabetes Complications Diseases 0.000 claims description 3
206010012655 Diabetic complications Diseases 0.000 claims description 3
230000002496 gastric effect Effects 0.000 claims description 3
UOAMFKUSJGXAJT-UHFFFAOYSA-N n-[5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 UOAMFKUSJGXAJT-UHFFFAOYSA-N 0.000 claims description 3
GKNRICGPGVNSOP-UHFFFAOYSA-N n-[5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 GKNRICGPGVNSOP-UHFFFAOYSA-N 0.000 claims description 3
MFFJWNLTOJTLIW-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-methoxyphenoxy)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=CC=C(OC)C=1OC=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 MFFJWNLTOJTLIW-UHFFFAOYSA-N 0.000 claims description 3
UZJPUBLRNMORBF-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(C)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 UZJPUBLRNMORBF-UHFFFAOYSA-N 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
NLDPFHPQEOXOJX-UHFFFAOYSA-N 6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-methoxyphenoxy)pyrimidin-4-amine Chemical compound COC1=CC=CC=C1OC1=C(N)N=CN=C1OCCOC1=NC=C(Br)C=N1 NLDPFHPQEOXOJX-UHFFFAOYSA-N 0.000 claims description 2
FRWIMGGYOINGHV-UHFFFAOYSA-N 6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-chlorophenyl)pyrimidin-4-amine Chemical compound C=1C=C(Cl)C=CC=1C=1C(N)=NC=NC=1OCCOC1=NC=C(Br)C=N1 FRWIMGGYOINGHV-UHFFFAOYSA-N 0.000 claims description 2
239000000654 additive Substances 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
KUQAVFMCAIVQEC-UHFFFAOYSA-N n-[5-(3-methoxyphenoxy)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]butane-1-sulfonamide Chemical compound C=1C=CC(OC)=CC=1OC=1C(NS(=O)(=O)CCCC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 KUQAVFMCAIVQEC-UHFFFAOYSA-N 0.000 claims description 2
GQNDHPXIBSVUKS-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-chloro-5-methoxyphenoxy)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C(OC)=CC=C(Cl)C=1OC=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 GQNDHPXIBSVUKS-UHFFFAOYSA-N 0.000 claims description 2
QLOACGMSZNOMDZ-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=CC=C(OC)C=1OC=1C(NS(=O)(=O)CCC)=NC(C=2N=CC=CN=2)=NC=1OCCOC1=NC=C(Br)C=N1 QLOACGMSZNOMDZ-UHFFFAOYSA-N 0.000 claims description 2
UIDBISUHXOJSFR-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-chlorophenyl)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(Cl)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 UIDBISUHXOJSFR-UHFFFAOYSA-N 0.000 claims description 2
KWYKEXOLXHZRMJ-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl]methanesulfonamide Chemical compound C1=CC(C)=CC=C1C1=C(NS(C)(=O)=O)N=CN=C1OCCOC1=NC=C(Br)C=N1 KWYKEXOLXHZRMJ-UHFFFAOYSA-N 0.000 claims description 2
206010040943 Skin Ulcer Diseases 0.000 claims 2
208000018631 connective tissue disease Diseases 0.000 claims 2
208000027866 inflammatory disease Diseases 0.000 claims 2
230000002062 proliferating effect Effects 0.000 claims 2
208000005069 pulmonary fibrosis Diseases 0.000 claims 2
238000001356 surgical procedure Methods 0.000 claims 2
201000006474 Brain Ischemia Diseases 0.000 claims 1
206010008118 cerebral infarction Diseases 0.000 claims 1
201000005917 gastric ulcer Diseases 0.000 claims 1
XPDOBCREVDGWNE-UHFFFAOYSA-N n-[5-(2-chloro-5-methoxyphenoxy)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C(OC)=CC=C(Cl)C=1OC=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 XPDOBCREVDGWNE-UHFFFAOYSA-N 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
239000000243 solution Substances 0.000 description 22
239000000843 powder Substances 0.000 description 19
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
238000003756 stirring Methods 0.000 description 16
-1 polypropylene Polymers 0.000 description 15
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 12
125000003118 aryl group Chemical group 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
102400000686 Endothelin-1 Human genes 0.000 description 11
101800004490 Endothelin-1 Proteins 0.000 description 11
239000002244 precipitate Substances 0.000 description 11
239000007787 solid Substances 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 10
239000012312 sodium hydride Substances 0.000 description 10
229910000104 sodium hydride Inorganic materials 0.000 description 10
239000013058 crude material Substances 0.000 description 9
102100040611 Endothelin receptor type B Human genes 0.000 description 8
201000010099 disease Diseases 0.000 description 8
229910052943 magnesium sulfate Inorganic materials 0.000 description 8
235000019341 magnesium sulphate Nutrition 0.000 description 8
239000002904 solvent Substances 0.000 description 8
230000027455 binding Effects 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000002425 crystallisation Methods 0.000 description 7
230000008025 crystallization Effects 0.000 description 7
239000000284 extract Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
125000004433 nitrogen atom Chemical group N* 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
229940118365 Endothelin receptor antagonist Drugs 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
239000002308 endothelin receptor antagonist Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
238000012360 testing method Methods 0.000 description 5
XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 4
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
230000008602 contraction Effects 0.000 description 4
239000005457 ice water Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
PIDMSKVCITVKPT-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=NC(C=2N=CC=CN=2)=NC(OCCO)=C1OC1=CC=CC=C1OC PIDMSKVCITVKPT-UHFFFAOYSA-N 0.000 description 4
ZPJJBACIDGNJTM-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(4-methylphenyl)pyrimidin-4-yl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=NC=NC(OCCO)=C1C1=CC=C(C)C=C1 ZPJJBACIDGNJTM-UHFFFAOYSA-N 0.000 description 4
JMTUMLJLZDTTPL-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(4-methylphenyl)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=NC=NC(OCCO)=C1C1=CC=C(C)C=C1 JMTUMLJLZDTTPL-UHFFFAOYSA-N 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
UGWJTFHCCZHCDI-UHFFFAOYSA-N 2-chloro-5-methylsulfanylpyrimidine Chemical compound CSC1=CN=C(Cl)N=C1 UGWJTFHCCZHCDI-UHFFFAOYSA-N 0.000 description 3
XCIYCYPBRIGCOY-UHFFFAOYSA-N 4,6-dichloro-5-(4-methylphenyl)pyrimidine Chemical compound C1=CC(C)=CC=C1C1=C(Cl)N=CN=C1Cl XCIYCYPBRIGCOY-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
210000000709 aorta Anatomy 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 3
125000001072 heteroaryl group Chemical group 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
KVBDMEGPOYNDLE-UHFFFAOYSA-N potassium propylsulfonylazanide Chemical compound [K+].CCCS([NH-])(=O)=O KVBDMEGPOYNDLE-UHFFFAOYSA-N 0.000 description 3
NVZORFFLHDKQPI-UHFFFAOYSA-N potassium;ethylsulfonylazanide Chemical compound [K+].CCS([NH-])(=O)=O NVZORFFLHDKQPI-UHFFFAOYSA-N 0.000 description 3
LXPHPKVWHQLBBA-UHFFFAOYSA-N sarafotoxin s6c Chemical compound C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C1NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C2CSSCC(C(NC(CC(N)=O)C(=O)NC(CC(O)=O)C(=O)NC(CCSC)C(=O)NC(C(=O)NC(CC(O)=O)C(=O)NC(CCC(O)=O)C(=O)NC(CCC(O)=O)C(=O)N2)C(C)O)=O)NC(=O)C(C(C)O)NC(=O)C(N)CSSC1)CC1=CN=CN1 LXPHPKVWHQLBBA-UHFFFAOYSA-N 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
125000004434 sulfur atom Chemical group 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
210000003437 trachea Anatomy 0.000 description 3
RSUBGBZOMBTDTI-UHFFFAOYSA-N 2-chloro-5-methoxypyrimidine Chemical compound COC1=CN=C(Cl)N=C1 RSUBGBZOMBTDTI-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
LHHADLIWXDJPLB-UHFFFAOYSA-N 4-hydroxy-5-(4-methylphenyl)-1h-pyrimidin-6-one Chemical compound C1=CC(C)=CC=C1C1=C(O)N=CN=C1O LHHADLIWXDJPLB-UHFFFAOYSA-N 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
102000010180 Endothelin receptor Human genes 0.000 description 2
108050001739 Endothelin receptor Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
206010047139 Vasoconstriction Diseases 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 description 2
229960003065 bosentan Drugs 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000007675 cardiac surgery Methods 0.000 description 2
239000012043 crude product Substances 0.000 description 2
230000000763 evoking effect Effects 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
229940012356 eye drops Drugs 0.000 description 2
239000003925 fat Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
KHGHGINGZRDHQJ-UHFFFAOYSA-N n-[5-(4-methylphenyl)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=C(C)C=CC=1C=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 KHGHGINGZRDHQJ-UHFFFAOYSA-N 0.000 description 2
CSYJJVCQYGWAPM-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=C(C)C=CC=1C=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 CSYJJVCQYGWAPM-UHFFFAOYSA-N 0.000 description 2
ILOGXQYAOBLTMP-UHFFFAOYSA-N n-[6-chloro-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=NC(C=2N=CC=CN=2)=NC(Cl)=C1OC1=CC=CC=C1OC ILOGXQYAOBLTMP-UHFFFAOYSA-N 0.000 description 2
WLNVWARHPFRSLG-UHFFFAOYSA-N n-[6-chloro-5-(4-methylphenyl)pyrimidin-4-yl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=NC=NC(Cl)=C1C1=CC=C(C)C=C1 WLNVWARHPFRSLG-UHFFFAOYSA-N 0.000 description 2
JWVFSXDDRJUDDX-UHFFFAOYSA-N n-[6-chloro-5-(4-methylphenyl)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=NC=NC(Cl)=C1C1=CC=C(C)C=C1 JWVFSXDDRJUDDX-UHFFFAOYSA-N 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
OVFOQDGJPJVPNL-UHFFFAOYSA-N tetrapotassium;butan-1-olate Chemical compound [K+].[K+].[K+].[K+].CCCC[O-].CCCC[O-].CCCC[O-].CCCC[O-] OVFOQDGJPJVPNL-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
210000005062 tracheal ring Anatomy 0.000 description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
238000007631 vascular surgery Methods 0.000 description 2
230000025033 vasoconstriction Effects 0.000 description 2
230000003639 vasoconstrictive effect Effects 0.000 description 2
229940124549 vasodilator Drugs 0.000 description 2
239000003071 vasodilator agent Substances 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000003643 water by type Substances 0.000 description 2
239000001993 wax Substances 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
HHJHAEAFTJQJCE-UHFFFAOYSA-N 2-chloropyrimidine-5-thiol Chemical compound SC1=CN=C(Cl)N=C1 HHJHAEAFTJQJCE-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
IZGOBGVYADHVKH-UHFFFAOYSA-N 4,6-dichloro-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidine Chemical group COC1=CC=CC=C1OC1=C(Cl)N=C(C=2N=CC=CN=2)N=C1Cl IZGOBGVYADHVKH-UHFFFAOYSA-N 0.000 description 1
125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
VZZFSIFKVARSJZ-UHFFFAOYSA-N 5-methoxy-2-methylsulfonylpyrimidine Chemical compound COC1=CN=C(S(C)(=O)=O)N=C1 VZZFSIFKVARSJZ-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
239000004072 C09CA03 - Valsartan Substances 0.000 description 1
239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108010007859 Lisinopril Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
208000007920 Neurogenic Inflammation Diseases 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000000219 Sympatholytic Substances 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000003302 alkenyloxy group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000005530 alkylenedioxy group Chemical group 0.000 description 1
125000005336 allyloxy group Chemical group 0.000 description 1
239000002160 alpha blocker Substances 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
NMVVJCLUYUWBSZ-UHFFFAOYSA-N aminomethylideneazanium;chloride Chemical compound Cl.NC=N NMVVJCLUYUWBSZ-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
229960004064 bumetanide Drugs 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000005569 butenylene group Chemical group 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229960001222 carteolol Drugs 0.000 description 1
LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
229960001523 chlortalidone Drugs 0.000 description 1
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
229960005025 cilazapril Drugs 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
229960004042 diazoxide Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
WGBSHZUHSDGHLV-UHFFFAOYSA-N diethyl 2-(4-methylphenyl)propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)C1=CC=C(C)C=C1 WGBSHZUHSDGHLV-UHFFFAOYSA-N 0.000 description 1
125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
230000007368 endocrine function Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960001606 flosequinan Drugs 0.000 description 1
UYGONJYYUKVHDD-UHFFFAOYSA-N flosequinan Chemical compound C1=C(F)C=C2N(C)C=C(S(C)=O)C(=O)C2=C1 UYGONJYYUKVHDD-UHFFFAOYSA-N 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
229960004553 guanabenz Drugs 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000004217 heart function Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
125000005350 hydroxycycloalkyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000036737 immune function Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
208000001286 intracranial vasospasm Diseases 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
229960002198 irbesartan Drugs 0.000 description 1
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
229960002394 lisinopril Drugs 0.000 description 1
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
229960002817 metolazone Drugs 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229960003632 minoxidil Drugs 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
PWNOKSRTFQPWLQ-UHFFFAOYSA-N n-[5-(2-methoxyphenoxy)-6-[2-(5-methoxypyrimidin-2-yl)oxyethoxy]-2-pyrimidin-2-ylpyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=CC=C(OC)C=1OC=1C(NS(=O)(=O)CC)=NC(C=2N=CC=CN=2)=NC=1OCCOC1=NC=C(OC)C=N1 PWNOKSRTFQPWLQ-UHFFFAOYSA-N 0.000 description 1
KJXLMLJDGVLVGJ-UHFFFAOYSA-N n-[5-(2-methoxyphenoxy)-6-[2-(5-methoxypyrimidin-2-yl)oxyethoxy]-2-pyrimidin-2-ylpyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=CC=C(OC)C=1OC=1C(NS(=O)(=O)CCC)=NC(C=2N=CC=CN=2)=NC=1OCCOC1=NC=C(OC)C=N1 KJXLMLJDGVLVGJ-UHFFFAOYSA-N 0.000 description 1
OHIYBHBEYDPXSX-UHFFFAOYSA-N n-[5-(2-methoxyphenoxy)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]-2-pyrimidin-2-ylpyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=CC=C(OC)C=1OC=1C(NS(=O)(=O)CC)=NC(C=2N=CC=CN=2)=NC=1OCCOC1=NC=C(SC)C=N1 OHIYBHBEYDPXSX-UHFFFAOYSA-N 0.000 description 1
VSECTFCBMYJVCK-UHFFFAOYSA-N n-[5-(2-methoxyphenoxy)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]-2-pyrimidin-2-ylpyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=CC=C(OC)C=1OC=1C(NS(=O)(=O)CCC)=NC(C=2N=CC=CN=2)=NC=1OCCOC1=NC=C(SC)C=N1 VSECTFCBMYJVCK-UHFFFAOYSA-N 0.000 description 1
OLLFRCFQYOKNBX-UHFFFAOYSA-N n-[5-(4-bromophenyl)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 OLLFRCFQYOKNBX-UHFFFAOYSA-N 0.000 description 1
XNAWWFWTHOCXCY-UHFFFAOYSA-N n-[5-(4-methylphenyl)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(C)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 XNAWWFWTHOCXCY-UHFFFAOYSA-N 0.000 description 1
UUILSFYNIDPDDJ-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]ethanesulfonamide Chemical compound CCS(=O)(=O)NC1=NC(C=2N=CC=CN=2)=NC(OCCO)=C1OC1=CC=CC=C1OC UUILSFYNIDPDDJ-UHFFFAOYSA-N 0.000 description 1
DXEAVENYJZCWCC-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-chloro-5-methoxyphenoxy)pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C(OC)=CC=C(Cl)C=1OC=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 DXEAVENYJZCWCC-UHFFFAOYSA-N 0.000 description 1
MDMATIORLXSDBS-UHFFFAOYSA-N n-[6-[2-(5-methoxypyrimidin-2-yl)oxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=C(C)C=CC=1C=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(OC)C=N1 MDMATIORLXSDBS-UHFFFAOYSA-N 0.000 description 1
UHDCRCGRILKFBI-UHFFFAOYSA-N n-[6-[2-(5-methoxypyrimidin-2-yl)oxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(C)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(OC)C=N1 UHDCRCGRILKFBI-UHFFFAOYSA-N 0.000 description 1
VMHBADPFEFUIAC-UHFFFAOYSA-N n-[6-chloro-5-(2-ethoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=NC(C=2N=CC=CN=2)=NC(Cl)=C1OC1=CC=CC=C1OCC VMHBADPFEFUIAC-UHFFFAOYSA-N 0.000 description 1
YANVOCKEKQMHEK-UHFFFAOYSA-N n-[6-chloro-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=NC(C=2N=CC=CN=2)=NC(Cl)=C1OC1=CC=CC=C1OC YANVOCKEKQMHEK-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000006259 organic additive Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000005981 pentynyl group Chemical group 0.000 description 1
229960003418 phenoxybenzamine Drugs 0.000 description 1
229960001999 phentolamine Drugs 0.000 description 1
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
229960002310 pinacidil Drugs 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
DROIHSMGGKKIJT-UHFFFAOYSA-N propane-1-sulfonamide Chemical compound CCCS(N)(=O)=O DROIHSMGGKKIJT-UHFFFAOYSA-N 0.000 description 1
KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 1
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
239000000523 sample Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
208000037905 systemic hypertension Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000010998 test method Methods 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960004699 valsartan Drugs 0.000 description 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Gynecology & Obstetrics (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20043215A 2002-01-02 2004-07-29 Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser NO327220B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP0200002		2002-01-02
PCT/EP2002/013970 WO2003055863A1 (fr)	2002-01-02	2002-12-10	Alcanesulfonamides en tant qu'antagonistes des endothelines

Publications (2)

Publication Number	Publication Date
NO20043215L NO20043215L (no)	2004-07-29
NO327220B1 true NO327220B1 (no)	2009-05-18

Family

ID=8164767

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20043215A NO327220B1 (no)	2002-01-02	2004-07-29	Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser

Country Status (20)

Country	Link
US (1)	US7323465B2 (fr)
JP (1)	JP4769418B2 (fr)
KR (1)	KR100940432B1 (fr)
CN (1)	CN100537546C (fr)
AR (1)	AR037943A1 (fr)
AT (1)	ATE381545T1 (fr)
AU (1)	AU2002361033B8 (fr)
BR (1)	BR0215424A (fr)
CA (1)	CA2471220C (fr)
DE (1)	DE60224223T2 (fr)
ES (1)	ES2297040T3 (fr)
HU (1)	HUP0500082A2 (fr)
IL (2)	IL162534A0 (fr)
MX (1)	MXPA04006457A (fr)
MY (1)	MY138502A (fr)
NO (1)	NO327220B1 (fr)
NZ (1)	NZ533693A (fr)
TW (1)	TWI248436B (fr)
WO (1)	WO2003055863A1 (fr)
ZA (1)	ZA200404927B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008120093A1 (fr) *	2007-04-03	2008-10-09	Pfizer Inc.	Sulfonamides et compositions pharmaceutiques les contenant
IT1393136B1 (it) *	2009-03-11	2012-04-11	Sifa Vitor S R L	Procedimento per la preparazione del bosentan
US20100256371A1 (en) *	2009-04-02	2010-10-07	Glenmark	Processes for the preparation of bosentan and its intermediates thereof
AR077999A1 (es) *	2009-09-02	2011-10-05	Vifor Int Ag	Antagonistas de pirimidin y triazin-hepcidina
EP2907811A1 (fr) *	2014-02-14	2015-08-19	Actelion Pharmaceuticals Ltd.	Procédé de fabrication de dérivés de sulfamide de pyrimidine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5739333A (en)	1995-05-16	1998-04-14	Tanabe Seiyaku Co., Ltd.	Sulfonamide derivative and process for preparing the same
JP3013752B2 (ja) *	1995-05-16	2000-02-28	田辺製薬株式会社	スルホンアミド誘導体
KR100456650B1 (ko) *	1995-12-20	2005-06-20	야마노우치세이야쿠 가부시키가이샤	아릴에텐설폰아미드유도체
WO1998003488A1 (fr) *	1996-07-23	1998-01-29	Shionogi & Co., Ltd.	Nouveaux composes a base de pyrimidine et compositions medicamenteuses
JP3116347B2 (ja) *	1996-11-13	2000-12-11	田辺製薬株式会社	医薬組成物
WO1998057938A1 (fr) *	1997-06-19	1998-12-23	Yamanouchi Pharmaceutical Co., Ltd.	Derives d'alcanesulfonamide inferieur substitue et composition pharmaceutique les contenant
CN100424079C (zh) *	1999-09-03	2008-10-08	埃科特莱茵药品有限公司	双磺胺
GB0023074D0 (en) *	2000-09-20	2000-11-01	Pfizer Ltd	Pyridazines

2002
- 2002-12-10 WO PCT/EP2002/013970 patent/WO2003055863A1/fr not_active Ceased
- 2002-12-10 AT AT02795133T patent/ATE381545T1/de active
- 2002-12-10 BR BR0215424-2A patent/BR0215424A/pt not_active IP Right Cessation
- 2002-12-10 NZ NZ533693A patent/NZ533693A/en not_active IP Right Cessation
- 2002-12-10 CN CNB028266447A patent/CN100537546C/zh not_active Expired - Fee Related
- 2002-12-10 MX MXPA04006457A patent/MXPA04006457A/es active IP Right Grant
- 2002-12-10 DE DE60224223T patent/DE60224223T2/de not_active Expired - Lifetime
- 2002-12-10 ES ES02795133T patent/ES2297040T3/es not_active Expired - Lifetime
- 2002-12-10 KR KR1020047010218A patent/KR100940432B1/ko not_active Expired - Fee Related
- 2002-12-10 AU AU2002361033A patent/AU2002361033B8/en not_active Ceased
- 2002-12-10 US US10/500,485 patent/US7323465B2/en not_active Expired - Fee Related
- 2002-12-10 JP JP2003556394A patent/JP4769418B2/ja not_active Expired - Fee Related
- 2002-12-10 HU HU0500082A patent/HUP0500082A2/hu unknown
- 2002-12-10 IL IL16253402A patent/IL162534A0/xx unknown
- 2002-12-10 CA CA2471220A patent/CA2471220C/fr not_active Expired - Fee Related
- 2002-12-19 AR ARP020105030A patent/AR037943A1/es active IP Right Grant
- 2002-12-26 TW TW091137487A patent/TWI248436B/zh not_active IP Right Cessation
- 2002-12-30 MY MYPI20024923A patent/MY138502A/en unknown
2004
- 2004-06-15 IL IL162534A patent/IL162534A/en not_active IP Right Cessation
- 2004-06-22 ZA ZA2004/04927A patent/ZA200404927B/en unknown
- 2004-07-29 NO NO20043215A patent/NO327220B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2297040T3 (es)	2008-05-01
AU2002361033A1 (en)	2003-07-15
TWI248436B (en)	2006-02-01
DE60224223T2 (de)	2008-12-04
US7323465B2 (en)	2008-01-29
MY138502A (en)	2009-06-30
CA2471220C (fr)	2010-11-16
AU2002361033B2 (en)	2008-11-20
NO20043215L (no)	2004-07-29
MXPA04006457A (es)	2004-10-04
US20050085639A1 (en)	2005-04-21
NZ533693A (en)	2007-02-23
IL162534A0 (en)	2005-11-20
KR20040073525A (ko)	2004-08-19
IL162534A (en)	2011-07-31
AU2002361033B8 (en)	2009-01-29
JP4769418B2 (ja)	2011-09-07
TW200404063A (en)	2004-03-16
CN100537546C (zh)	2009-09-09
AR037943A1 (es)	2004-12-22
ATE381545T1 (de)	2008-01-15
CN1612864A (zh)	2005-05-04
WO2003055863A1 (fr)	2003-07-10
JP2005513155A (ja)	2005-05-12
KR100940432B1 (ko)	2010-02-10
DE60224223D1 (de)	2008-01-31
BR0215424A (pt)	2004-12-14
HUP0500082A2 (hu)	2005-04-28
CA2471220A1 (fr)	2003-07-10
ZA200404927B (en)	2005-11-30

Legal Events

Date	Code	Title	Description
2012-07-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
EP1345920B1 (fr)	2006-04-12	Nouveaux sulfamides et leur utilisation comme antagonistes du recepteur de l'endotheline
US6596719B1 (en)	2003-07-22	6 alkoxy-4-pyrimidinyl bis-sulfonamides
US7091201B2 (en)	2006-08-15	Arylalkane-sulfonamides having endothelin-antagonist activity
EP1309564B1 (fr)	2006-06-14	Nouveaux sulfonamides arylethene
AU2002212171A1 (en)	2002-06-20	Arylalkane-sulfonamides having endothelin-antagonist activity
AU2001281970A1 (en)	2002-05-02	Arylethene-sulfonamides, their preparation and their use as endothelin antagonists
WO2001081335A1 (fr)	2001-11-01	Pyrimidine-sulfonamides agissant comme antagonistes de l'endotheline
CA2471220C (fr)	2010-11-16	Alcanesulfonamides en tant qu'antagonistes des endothelines
WO2002083650A1 (fr)	2002-10-24	Nouvelles sulfonylamino-pyrimidines
EP1322624B1 (fr)	2009-10-21	Arylalcane-sulfonamides
EP1465875B1 (fr)	2007-12-19	Alcanesulfonamides en tant qu'antagonistes des endothelines